A single batch of a life-saving rabies vaccine just failed India's toughest safety test.
And the timing couldn't be scarier.
India records 3.71 million dog-bite cases every year.
54 suspected human rabies deaths annually.
Once symptoms show up, it's almost 100% fatal.
No cure. No second chances.
So when a vaccine batch fails, people panic.
Here's exactly what happened.
The Central Drugs Laboratory in Kasauli tested a batch of Bio-Med's SURE RAB vaccine.
Manufactured in November 2025. Meant to stay valid till 2028.
It failed two critical checks:
🦠 Bacterial endotoxin test — checks for harmful bacterial contamination
🐄 Bovine serum albumin test — checks for excess residual animal protein from manufacturing
Both exist for one reason: purity.
And this batch didn't pass.
This wasn't discovered after the vaccine hit a clinic shelf.
It was caught during mandatory pre-distribution testing — the checkpoint every batch must clear before it ever reaches a hospital.
Meaning: it never left the factory.
Never entered the market.
Never reached a single patient.
The system did exactly what it was built to do.
Bio-Med's managing director S.P. Garg didn't dodge the question.
"The issue is related to only one batch," he said.
👉 The company makes 15+ batches a month.
👉 All the others passed.
👉 The flagged batch was discarded, as required by law.
"These manufacturing technologies are extremely difficult," he added.
India's rabies vaccine market is worth roughly ₹125 crore.
Bio-Med shares that space with Serum Institute, Bharat Biotech, and Indian Immunologicals.
Public health expert Dr Rajeev Jayadevan put it simply:
"This does not mean vaccines available for public use are unsafe."
He called it proof the surveillance system works — not proof the system is broken.
But he had one non-negotiable reminder:
If you get bitten, get vaccinated immediately.
Rabies waits for no one.
One failed batch made headlines.
But zero failed batches reached the public.
That's not a scandal.
That's a safety net doing its job.
That's all for now!
